載入...
Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects
Since sodium stibogluconate (SSG) inhibited phosphatases including SHP-1 and augmented anti-tumor actions of IFN-α2b in vitro and in mice, two Phase I trials of SSG/IFN-α2b combination were undertaken to evaluate safety and target inhibition. Escalating doses of SSG (200-1200 mg/m(2)) and fixed dose...
Na minha lista:
Main Authors: | , , , , , , , , |
---|---|
格式: | Artigo |
語言: | Inglês |
出版: |
Impact Journals LLC
2011
|
主題: | |
在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3282074/ https://ncbi.nlm.nih.gov/pubmed/22201704 |
標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|